netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.06.02  Expand sub section  Calcium-channel blockers
Amlodipine
View adult BNF View SPC online
First Choice Tablets: 5mg, 10mg 
Diltiazem
View adult BNF View SPC online
First Choice Tablets: 60mg
SR preparation (twice daily): 60mg, 90mg, 120mg, 180mg
XL preparation (once daily): 120mg, 180mg, 200mg, 240mg, 300mg, 360mg

Must be prescribed by brand 
Nifedipine
View adult BNF View SPC online
Formulary Capsules: 5mg, 10mg
Oral drops: 20mg/ml*
*Hospital use only 
   
Nifedipine modified release
View adult BNF View SPC online
Formulary Tablets: 10mg, 20mg, 30mg 60mg

Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of nifedipine, prescribers should specify the brand to be dispensed. Modified-release formulations may not be suitable for dose titration in hepatic disease 
   
Felodipine
(Only to be used where amlodipine and lercanidipine have been trialled first)
View adult BNF View SPC online
Alternatives M/R tablets: 2.5mg, 5mg, 10mg 
   
Lercanidipine
View adult BNF View SPC online
Alternatives Tablets: 10mg, 20mg 
   
Nimodipine
View adult BNF View SPC online
Alternatives
Red
Tablets: 30mg
Infusion: 0.02% 
   
Verapamil
View adult BNF View SPC online
Alternatives Tablets: 40mg, 80mg, 120mg
SR Tablets: 120mg, 240mg
Oral solution: 40mg/5ml
MR Capsules: 180mg 
   
Verapamil
View adult BNF View SPC online
Alternatives
Red
Injection: 5mg/2ml (2.5mg/1ml) 
   
 ....
 Non Formulary Items
Amlodipine and Valsartan  (Exforge)

View adult BNF View SPC online
Non Formulary
 
Isradipine  (Prescal)

View adult BNF View SPC online
Non Formulary
 
Lacidipine  (Motens®)

View adult BNF View SPC online
Non Formulary
 
Nicardipine  (Cardene)

View adult BNF View SPC online
Non Formulary
 
Nisoldipine  (Syscor® MR)

View adult BNF View SPC online
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

Amber

These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

Green +

Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

Green

These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

netFormulary